title: Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa.
abstract: In a randomized phase III trial, sunitinib was associated with significantly superior progression-free survival when compared with interferon alfa as first-line therapy in patients with metastatic renal cell carcinoma. This article investigates whether baseline quality of life and demographic and clinical variables were predictive for progression-free survival.
authors.affiliation: Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, IL; Pfizer Global Research and Development, Groton, CT, La Jolla, CA, and New York; Memorial Sloan-Kettering Cancer Center, New York, NY; and Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: David
authors.initials: D
authors.lastname: Cella
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Cappelleri
authors.forename: Andrew
authors.initials: A
authors.lastname: Bushmakin
authors.forename: Claudie
authors.initials: C
authors.lastname: Charbonneau
authors.forename: Jim Z
authors.initials: JZ
authors.lastname: Li
authors.forename: Sindy T
authors.initials: ST
authors.lastname: Kim
authors.forename: Isan
authors.initials: I
authors.lastname: Chen
authors.forename: M Dror
authors.initials: MD
authors.lastname: Michaelson
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Motzer